Janet L. Espirito

1.0k total citations
53 papers, 687 citations indexed

About

Janet L. Espirito is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Janet L. Espirito has authored 53 papers receiving a total of 687 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Janet L. Espirito's work include Lung Cancer Treatments and Mutations (20 papers), Cancer Genomics and Diagnostics (11 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Janet L. Espirito is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Cancer Genomics and Diagnostics (11 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Janet L. Espirito collaborates with scholars based in United States, Germany and Netherlands. Janet L. Espirito's co-authors include Nicholas J. Robert, C. Lance Cowey, Marcus A. Neubauer, Ancilla W. Fernandes, Lisa Mahnke, Murtuza Bharmal, Christoph Helwig, Marley Boyd, Melissa Pavilack and Eric Nadler and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Janet L. Espirito

47 papers receiving 673 citations

Peers

Janet L. Espirito

ONCOL

PRM

EPIDE

Anne‐Valérie Guizard France

Zoé Uhry France

B. Lapôtre‐Ledoux France

Marley Boyd United States

Vinayak Muralidhar United States

Jason C. Barnett United States

D. Greenberg United Kingdom

Ash Bullement United Kingdom

Kari Tyne Switzerland

Marta Román Spain

Anne‐Valérie Guizard France

Janet L. Espirito

259 ×0.6

ONCOL

160 ×0.6

PRM

53 ×0.3

39 ×0.3

165 ×2.1

EPIDE

Citations per year, relative to Janet L. Espirito Janet L. Espirito (= 1×) peers Anne‐Valérie Guizard

Countries citing papers authored by Janet L. Espirito

Since Specialization

Citations

This map shows the geographic impact of Janet L. Espirito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet L. Espirito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet L. Espirito more than expected).

Fields of papers citing papers by Janet L. Espirito

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet L. Espirito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet L. Espirito. The network helps show where Janet L. Espirito may publish in the future.

Co-authorship network of co-authors of Janet L. Espirito

This figure shows the co-authorship network connecting the top 25 collaborators of Janet L. Espirito. A scholar is included among the top collaborators of Janet L. Espirito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet L. Espirito. Janet L. Espirito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Espirito, Janet L., et al.. (2025). Evaluating the Minimal Common Oncology Data Elements Suitability in Enhancing Clinical Observational Research. JCO Clinical Cancer Informatics. 9(9). e2500065–e2500065.

Goldschmidt, Jerome H., Wan‐Yu Tseng, Yunfei Wang, et al.. (2024). Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations Previously Treated with Platinum-Based Chemotherapy and Immunotherapy. Drugs - Real World Outcomes. 11(3). 425–439.

Wilson, Thomas W., et al.. (2023). Feasibility of Using Oncology-Specific Electronic Health Record (EHR) Data to Emulate Clinical Trial Eligibility Criteria. SHILAP Revista de lepidopterología. 2(2). 140–147.

Denduluri, Neelima, et al.. (2022). Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States. Drugs - Real World Outcomes. 10(2). 177–186. 1 indexed citations

Robert, Nicholas J., Janet L. Espirito, Liwei Chen, et al.. (2022). Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network. Lung Cancer. 166. 197–204. 45 indexed citations

Boyd, Marley, et al.. (2021). PCN233 Concordance of Clinical Vs. Algorithm Based Line of Therapy Determination in Lung Cancer. Value in Health. 24. S63–S63.

Waterhouse, David, et al.. (2021). Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists. Clinical Lung Cancer. 22(6). e901–e910. 24 indexed citations

Robert, Nicholas J., Janet L. Espirito, Li-Wei Chen, et al.. (2021). Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.. Journal of Clinical Oncology. 39(15_suppl). 9004–9004. 33 indexed citations

Waterhouse, David, Laura Iadeluca, Keith D. Wilner, et al.. (2021). Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study. Targeted Oncology. 17(1). 25–33. 10 indexed citations

10.

Nadler, Eric, et al.. (2020). Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. Advances in Therapy. 37(2). 946–954. 18 indexed citations

11.

Boyd, Marley, Srinivas Annavarapu, Kathleen M. Aguilar, et al.. (2020). PCN1 CONCORDANCE OF DEATH DATE ASSESSMENTS BETWEEN THE SOCIAL SECURITY DEATH MASTER FILE AND ELECTRONIC HEALTH RECORDS IN A US COMMUNITY ONCOLOGY SETTING. Value in Health. 23. S22–S22. 4 indexed citations

12.

Waterhouse, David, Janet L. Espirito, Marc Chioda, et al.. (2020). Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer. Drugs - Real World Outcomes. 7(4). 261–269. 14 indexed citations

13.

Robert, Nicholas J., et al.. (2019). PCN301 DEVELOPMENT OF PLAYBOOK FOR CHART REVIEW IN REAL WORLD DATA. Value in Health. 22. S113–S113. 1 indexed citations

14.

Nadler, Eric, et al.. (2018). MA08.06 Outcomes Among Patients with EGFR-Mutant Metastatic NSCLC with and without Brain Metastases. Journal of Thoracic Oncology. 13(10). S383–S383. 1 indexed citations

15.

Nadler, Eric, et al.. (2018). Treatment Patterns and Clinical Outcomes Among Metastatic Non–Small-Cell Lung Cancer Patients Treated in the Community Practice Setting. Clinical Lung Cancer. 19(4). 360–370. 38 indexed citations

16.

Cartwright, Thomas H., Monika Parisi, Janet L. Espirito, et al.. (2018). Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting. Drugs - Real World Outcomes. 5(3). 149–159. 33 indexed citations

17.

Bookman, Michael A., Jerzy E. Tyczynski, Janet L. Espirito, Thomas W. Wilson, & Ancilla W. Fernandes. (2017). Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. Gynecologic Oncology. 146(1). 58–63. 21 indexed citations

18.

Reynolds, Craig H., Elizabeth T. Masters, Jack Mardekian, et al.. (2017). P3.02a-019 Real World Utilization and Outcomes of ALK-Positive Crizotinib Treated Metastatic NSCLC Patients in US Community Oncology Practice. Journal of Thoracic Oncology. 12(1). S1172–S1173. 1 indexed citations

19.

Cowey, C. Lance, Lisa Mahnke, Janet L. Espirito, et al.. (2016). Real-World Outcomes of Patients with Metastatic Merkel Cell Carcinoma Treated with Second-Line or Later Chemotherapy in A Community Oncology Setting in The United States. Value in Health. 19(7). A717–A717. 4 indexed citations

20.

Verrilli, Diana K., et al.. (2015). Cost differential by site of service for cancer patients receiving chemotherapy.. PubMed. 21(3). e189–96. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact